Skip to main content

Advertisement

Table 2 Sensitivity-analysis of the effect of corticosteroid prophylaxis of post-ERCP pancreatitis in clinical trials

From: Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis

Method Patients Pooled OR (95% CI) p
  PEP
A 2632 1.13 (0.89, 1.44) 0.32
B 2328 1.20 (0.93, 1.55) 0.17
C 2247 1.10 (0.85, 1.43) 0.47
D 2448 1.13 (0.88, 1.46) 0.34
  Severe PEP
A 2257 1.61 (0.74, 3.52) 0.23
B 2073 1.80 (0.68, 4.72) 0.23
C 1872 1.35 (0.47, 3.91) 0.58
D 2073 1.80 (0.68, 4.72) 0.23
  Post-ERCP hyperamylasemia
A 412 0.92 (0.57, 1.48) 0.73
B 228 0.87 (0.52, 1.46) 0.60
C 228 0.87 (0.52, 1.46) 0.60
D 228 0.87 (0.52, 1.46) 0.60
  1. A: all included trials [18–24]
  2. B: we excluded the trials that the allocation concealment was inadequate or unclear [18, 24]
  3. C: we excluded the trials that the blindness was unadopted [18, 21]
  4. D: we excluded the trials which published in the form of abstract [18]